Chester County News and Community Website
BERWYN, PA — Panavance Therapeutics Inc. is a new clinical-stage pharmaceutical company created to advance and develop GP-2250, a patented, novel therapeutic for the treatment of cancer and other therapeutic …
Read More
WASHINGTON, D.C. — Yesterday, Representatives Chrissy Houlahan (D-PA) and Peter Meijer (R-MI) introduced H.R. 6374, the House companion to the Strengthening Supply Chains for Servicemembers and Security Act. This timely …
Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has provided an update on the status of certain of its clinical programs and on its research and development (R&D) operations.
Read More
BERWYN, PA — AscellaHealth recently announced the unveiling of a more robust, streamlined website with easy-to-navigate content featuring its innovative programs and services for key market sectors: patients – the …
Read More
BERWYN, PA — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) announced it recently signed a clinical trial agreement with Altasciences Company, Inc. for a First in Human study investigating Epoladerm™ for pain …
Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) recently reported positive results following the completion of a toxicology and pharmacokinetic study designed to support clinical trials with Epoladerm™, one of …
Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that this week it has resubmitted the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) …
Read More
WASHINGTON, D.C. — The Biden-Harris Administration took additional steps this past week to lower health care costs by requiring health insurance issuers, employer-based health plans, and other group health plans …
Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. announced that the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) recently awarded research and development contracts to …
Read More
WASHINGTON, D.C. — The Federal Trade Commission will require generic drug marketers ANI Pharmaceuticals, Inc. and Novitium Pharma LLC to divest, to Prasco LLC, ANI’s development rights to one generic …
Read More